262 related articles for article (PubMed ID: 1359441)
1. Further studies of the role of opioid receptors in the nigra in the morphine withdrawal syndrome.
Baumeister AA; Richard AL; Richmond-Landeche L; Hurry MJ; Waguespack AM
Neuropharmacology; 1992 Sep; 31(9):835-41. PubMed ID: 1359441
[TBL] [Abstract][Full Text] [Related]
2. The effects of bilateral intranigral microinjection of selective opioid agonists on behavioral responses to noxious thermal stimuli.
Baumeister AA
Brain Res; 1991 Aug; 557(1-2):136-45. PubMed ID: 1660749
[TBL] [Abstract][Full Text] [Related]
3. Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues.
Gouardères C; Jhamandas K; Sutak M; Zajac JM
Br J Pharmacol; 1996 Feb; 117(3):493-501. PubMed ID: 8821539
[TBL] [Abstract][Full Text] [Related]
4. The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons.
Chieng B; Connor M; Christie MJ
Mol Pharmacol; 1996 Sep; 50(3):650-5. PubMed ID: 8794906
[TBL] [Abstract][Full Text] [Related]
5. Mu- and delta-opioid receptor antagonists precipitate similar withdrawal phenomena in butorphanol and morphine dependence.
Feng YZ; Zhang T; Tokuyama S; Zhu H; Rockhold RW; Ho IK
Neurochem Res; 1996 Jan; 21(1):63-71. PubMed ID: 8833225
[TBL] [Abstract][Full Text] [Related]
6. The antinociceptive and motivational effects of intranigral injection of opioid agonists.
Baumeister AA; Hurry M; Curtis W; Chaney TM; Wolf E; Leoni RR
Neuropharmacology; 1993 Dec; 32(12):1299-303. PubMed ID: 8152521
[TBL] [Abstract][Full Text] [Related]
7. Central effects of the potent and highly selective mu opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice.
Gulya K; Kriván M; Nyolczas N; Sarnyai Z; Kovács GL
Eur J Pharmacol; 1988 Jun; 150(3):355-60. PubMed ID: 2901358
[TBL] [Abstract][Full Text] [Related]
8. Focal kappa-opioid receptor-mediated dependence and withdrawal in the nucleus paragigantocellularis.
Sinchaisuk S; Ho IK; Rockhold RW
Pharmacol Biochem Behav; 2002 Dec; 74(1):241-52. PubMed ID: 12376173
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
Mjanger E; Yaksh TL
J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
[TBL] [Abstract][Full Text] [Related]
10. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
11. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
12. Differences in physical dependence induced by selective mu or delta opioid agonists and by endogenous enkephalins protected by peptidase inhibitors.
Maldonado R; Feger J; Fournié-Zaluski MC; Roques BP
Brain Res; 1990 Jun; 520(1-2):247-54. PubMed ID: 2169953
[TBL] [Abstract][Full Text] [Related]
13. Effects in the rat of intranigral morphine and DAGO on eating and gnawing induced by stress.
Hawkins MF; Fuller RD; Baumeister AA; McCallum MD
Pharmacol Biochem Behav; 1994 Nov; 49(3):737-40. PubMed ID: 7862730
[TBL] [Abstract][Full Text] [Related]
14. Enkephalin analog, cyclo[N(ε),N(β)-carbonyl-D-Lys(2),Dap(5)] enkephalinamide (cUENK6), inhibits the ethanol withdrawal-induced anxiety-like behavior in rats.
Gibula-Bruzda E; Marszalek-Grabska M; Witkowska E; Izdebski J; Kotlinska JH
Alcohol; 2015 May; 49(3):229-36. PubMed ID: 25716198
[TBL] [Abstract][Full Text] [Related]
15. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
16. Different types of opioid receptors mediating analgesia induced by morphine, DAMGO, DPDPE, DADLE and beta-endorphin in mice.
Suh HH; Tseng LF
Naunyn Schmiedebergs Arch Pharmacol; 1990 Jul; 342(1):67-71. PubMed ID: 1976234
[TBL] [Abstract][Full Text] [Related]
17. Precipitation of spinally mediated withdrawal signs by intrathecal administration of naloxone and the mu-receptor antagonist CTP in morphine-dependent mice.
Shook J; Kazmierski W; Hruby V; Burks T
NIDA Res Monogr; 1988; 81():143-8. PubMed ID: 2900467
[TBL] [Abstract][Full Text] [Related]
18. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies.
Devine DP; Leone P; Pocock D; Wise RA
J Pharmacol Exp Ther; 1993 Sep; 266(3):1236-46. PubMed ID: 7690399
[TBL] [Abstract][Full Text] [Related]
19. Electrophysiological demonstration of mu, delta and kappa opioid receptors in the ventral pallidum.
Mitrovic I; Napier TC
J Pharmacol Exp Ther; 1995 Mar; 272(3):1260-70. PubMed ID: 7891342
[TBL] [Abstract][Full Text] [Related]
20. Evidence for mu opioid receptor mediation of enkephalin-induced electroencephalographic seizures.
Tortella FC; Robles L; Mosberg HI
J Pharmacol Exp Ther; 1987 Feb; 240(2):571-7. PubMed ID: 3027318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
